# Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)

> **NCT00390728** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 2346 (—)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT00390728
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 2346 (—)
- **Last updated:** 2010-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390728, "Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00390728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*